The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.
Recent developments, however, suggest that strategies to treat pain are starting to match its complexity with a new sophistication. The management of chronic pain in general is now being broadly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback